Document Detail

Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency.
Jump to Full Text
MedLine Citation:
PMID:  23434938     Owner:  NLM     Status:  MEDLINE    
Glucagon-like peptide 1 (GLP-1) is a peptide hormone that is released from the gut in response to nutrient ingestion and that has a range of metabolic effects, including enhancing insulin secretion and decreasing food intake. Postprandial GLP-1 secretion is greatly enhanced in rats and humans after some bariatric procedures, including vertical sleeve gastrectomy (VSG), and has been widely hypothesized to contribute to reduced intake, weight loss, and the improvements in glucose homeostasis after VSG. We tested this hypothesis using two separate models of GLP-1 receptor deficiency. We found that VSG-operated GLP-1 receptor-deficient mice responded similarly to wild-type controls in terms of body weight and body fat loss, improved glucose tolerance, food intake reduction, and altered food selection. These data demonstrate that GLP-1 receptor activity is not necessary for the metabolic improvements induced by VSG surgery.
Hilary E Wilson-Pérez; Adam P Chambers; Karen K Ryan; Bailing Li; Darleen A Sandoval; Doris Stoffers; Daniel J Drucker; Diego Pérez-Tilve; Randy J Seeley
Related Documents :
15992928 - Assessment of marine pollution in izmir bay: nutrient, heavy metal and total hydrocarbo...
3340618 - Bioavailability of copper to rats from various foodstuffs and in the presence of differ...
18614278 - Evaluation of the distribution patterns of pb, cu and cd from mswi fly ash during therm...
15350688 - Estimates of trace metal bioavailability to humans ingesting contaminated oysters.
11307888 - Comparisons of microbiological evaluations of selected kitchen areas with visual inspec...
1800618 - The impact of partial termination of food subsidy programme on food consumption pattern.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2013-02-22
Journal Detail:
Title:  Diabetes     Volume:  62     ISSN:  1939-327X     ISO Abbreviation:  Diabetes     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-06-26     Completed Date:  2013-09-09     Revised Date:  2014-10-16    
Medline Journal Info:
Nlm Unique ID:  0372763     Medline TA:  Diabetes     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2380-5     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Body Composition / drug effects,  physiology*
Body Weight / drug effects,  physiology
Eating / drug effects,  physiology
Gastrectomy / methods*
Glucagon-Like Peptide 1 / metabolism
Insulin Resistance / physiology
Mice, Knockout
Obesity / genetics,  metabolism,  surgery*
Peptides / pharmacology
Postprandial Period
Receptors, Glucagon / genetics*,  metabolism
Venoms / pharmacology
Grant Support
Reg. No./Substance:
0/Peptides; 0/Receptors, Glucagon; 0/Venoms; 0/glucagon-like peptide-1 receptor; 89750-14-1/Glucagon-Like Peptide 1; 9P1872D4OL/exenatide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Diabetes
Journal ID (iso-abbrev): Diabetes
Journal ID (hwp): diabetes
Journal ID (pmc): diabetes
Journal ID (publisher-id): Diabetes
ISSN: 0012-1797
ISSN: 1939-327X
Publisher: American Diabetes Association
Article Information
Download PDF
© 2013 by the American Diabetes Association.
Received Day: 29 Month: 10 Year: 2012
Accepted Day: 19 Month: 2 Year: 2013
Print publication date: Month: 7 Year: 2013
Electronic publication date: Day: 14 Month: 6 Year: 2013
Volume: 62 Issue: 7
First Page: 2380 Last Page: 2385
PubMed Id: 23434938
ID: 3712071
Publisher Id: 1498
DOI: 10.2337/db12-1498

Vertical Sleeve Gastrectomy Is Effective in Two Genetic Mouse Models of Glucagon-Like Peptide 1 Receptor Deficiency
Hilary E. Wilson-Pérez1
Adam P. Chambers1
Karen K. Ryan1
Bailing Li1
Darleen A. Sandoval1
Doris Stoffers2
Daniel J. Drucker3
Diego Pérez-Tilve1
Randy J. Seeley1
1Department of Internal Medicine, Metabolic Diseases Institute, University of Cincinnati, Cincinnati, Ohio
2Institute for Diabetes, Obesity, and Metabolism and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
3Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
Correspondence: Corresponding author: Randy J. Seeley,

Glucagon-like peptide 1 (GLP-1) is a peptide hormone that is released from L-cells of the small intestine in response to nutrient ingestion. GLP-1 is most well-known for its effect as an incretin, stimulating insulin secretion from pancreatic β cells, but it also has a wide range of other effects, including the reduction of food intake and improvement of various aspects of glucose tolerance beyond its ability to augment insulin secretion. Long-acting GLP-1 receptor agonists are used as therapies for type 2 diabetes and convey the additional benefit of weight loss in many patients (1).

Bariatric surgery is the most effective weight loss treatment, surpassing drug therapies and lifestyle interventions (2). Vertical sleeve gastrectomy (VSG) is a bariatric procedure that involves the removal of ∼80% of the stomach along the greater curvature, creating a gastric “sleeve” in continuity with the esophagus and pylorus. VSG induces loss of body weight and fat mass and improves glucose tolerance in humans and in rodent models (38). For example, a recent randomized controlled trial that compared VSG, Roux-en-Y gastric bypass (RYGB), and medical management (9) found that VSG and RYGB produced similar percentage of patients whose diabetes had gone into remission after 1 year and both procedures were significantly superior to medical management. Although RYGB classically has been considered the gold standard for bariatric procedures, VSG is rapidly gaining in popularity and its utilization is increasing. Consequently, it is an important research and clinical goal to understand the underlying mechanisms for these potent effects of VSG.

Multiple reports show that weight-reduction bariatric procedures such as VSG and RYGB result in dramatically enhanced meal-stimulated GLP-1 secretion (6,10,11), leading to the hypothesis that GLP-1 action underlies many of the metabolic improvements caused by these surgeries. GLP-1 has one known receptor (GLP-1r), and mice that lack this receptor (GLP-1r knockout [KO]) are insensitive to the effects of exogenously administered GLP-1. These mice have impaired glucose tolerance (12,13). We tested the hypothesis that GLP-1 action is necessary for the effects of VSG by performing VSG surgery in two separate models of whole-body GLP-1r deficiency and by examining their metabolic and behavioral outcomes.


All procedures for animal use were approved by the University of Cincinnati Institutional Animal Care and Use Committee. Mice were maintained on a 12-h/12-h light–dark cycle with light onset at 1:00 A.M.

Experiment 1.

A cohort of C57B6 mice used to determine postprandial GLP-1 levels after VSG were bred in-house from breeders purchased from Jackson Laboratories and maintained on a high-fat butter-based diet (D12492 [60% fat, 5.24 kcal/g]; Research Diets, New Brunswick, NJ). Weight-matched mice received either VSG (n = 5) or sham (n = 7) surgery. At 12 weeks postoperatively, mice were fasted for 4 h in the middle of the light cycle before receiving a gavage of 200 μL of Ensure Plus liquid diet; 15 min later, mice were placed briefly in a CO2 chamber and were then killed by decapitation. Trunk blood was collected in tubes treated with a protease inhibitor cocktail of EDTA, Aprotinin, and heparin, and 25 μL plasma was used for measurement of GLP-1 (Meso Scale Discovery, Gaithersburg, MD).

Experiment 2.

GLP-1r wild-type (WT) and KO mice (13) were generated from homozygous breeding pairs, which were F1 offspring from GLP-1r heterozygote breeders. KO (n = 31) and WT (n = 24) mice were placed on a high-fat butter-based diet (D03082706 [40% fat, 4.54 kcal/g]; Research Diets, New Brunswick, NJ) for 5 weeks starting at age 4–8 weeks, at which point each was subdivided into 2 body weight and fat mass–matched groups (VSG and sham) before gastric surgery. Postoperative deaths, mainly within the first week, yielded final group numbers of 8 WT sham, 11 WT VSG, 12 KO sham, and 16 KO VSG. Common reasons for postoperative death included bleeding, infection, and gastric obstruction. The mice were maintained on high-fat diet after surgery except during the immediate postoperative period and during diet choice testing, as noted. Body weight and food intake were measured by weighing the mice and their food hoppers daily or weekly. A continuous monitoring system (TSE Systems, Chesterfield, MO) was used to obtain detailed food intake data from days 28–31.


VSG surgery was performed using isofluorane anesthesia. The lateral 80% of the stomach was excised, leaving a tubular gastric remnant in continuity with the esophagus superiorly and the pylorus and duodenum inferiorly. The sham procedure involved analogous isolation of the stomach followed by manually applying pressure with blunt forceps along a vertical line between the esophageal sphincter and the pylorus. Mice consumed liquid diet (Osmolite OneCal) for the first 4 postoperative days and were reintroduced to solid food (high-fat diet) on day 4.

Macronutrient selection.

Food choice was assayed from postoperative days 11–17 using a macronutrient selection paradigm in which three pure macronutrient diets (TD.02521 [carbohydrate], TD.02522 [fat], and TD02523 [protein]; Harlan Teklad) were presented simultaneously in separate containers. The first 2 days were acclimation, and data from the final 4 days are presented. Because of diet spillage by some mice, analysis was limited to six WT sham, seven WT VSG, nine KO sham, and 12 KO VSG mice.

Body composition.

Magnetic resonance imaging was performed on day 21 to determine body composition using a whole-body composition analyzer (EchoMedical Systems, Houston, TX).

Mixed-meal tolerance test.

A mixed-meal tolerance test was performed on postoperative day 18. Mice were fasted for 4 h beginning 5 h after the initiation of the light phase of the light–dark cycle. After a baseline blood sample was taken (0 min), 200 μL Ensure Plus liquid diet (1.41 kcal/g, 29% fat; Abbott Nutrition, Columbus, OH) was delivered by intragastric gavage. Blood glucose was measured at 0, 15, 30, 45, 60, and 120 min after nutrient administration on duplicate samples using Accu-chek glucometers and test strips (Roche, Indianapolis, IN). All blood samples were obtained from the tip of the tail vein of freely moving mice. An additional 50 μL blood was collected in heparinized tubes at times 0 min and 15 min to measure plasma insulin concentration. Blood was cold-centrifuged and plasma was stored at −80°C until insulin was assessed by ELISA (CrystalChem, Downers Grove, IL).

Anorexic response to exendin-4.

On day 41, all mice were fasted for 4 h before the onset of the dark phase of the light–dark cycle (t = −4 h). Exendin-4 (400 μg/kg, intraperitoneal) was injected at −1 h, and food was returned at 0 h. Food intake was measured at 2, 4, and 24 h. On the previous day, a procedurally identical experiment was conducted using an injection of intraperitoneal saline. Data shown are the difference in food intake per mouse between exendin-4 treatment and saline treatment.

Experiment 3.

We generated a separate mouse model of GLP-1r deficiency using a Cre-lox system, as described (Supplementary Fig. 1). Briefly, we generated mice with loxP sites flanking exons 6 and 7 of the GLP-1r gene and crossed them with mice that express Cre recombinase driven by the cytomegalovirus minimal (CMV) promoter. In CMV-Cre mice, deletion of loxP-flanked genes occurs in all tissues, including germ cells (14). Thus, mice that are homozygous for GLP-1r flox and hemizygous for CMV-Cre (GLP-1r flΔCMV) lack the GLP-1r in all tissues. Littermates that were hemizygous for CMV-Cre and WT for the GLP-1r (CMV-Cre) were used as controls. Gene expressions of GLP-1r exons 6 and 7 were determined by quantitative PCR and normalized to expression of L32. Experimental procedures, including surgery, mixed-meal tolerance test, and the anorexic response to exendin-4, were determined as described for experiment 2. Group sizes were as follows: 7 in CMV-Cre sham group, 7 in CMV-Cre VSG group, 11 in GLP-1r flΔCMV sham group, and 17 in GLP-1r flΔCMV VSG group. The mixed-meal tolerance test was performed 5 weeks after surgery, and the food intake response to exendin-4 was conducted 10 weeks later.


All data are presented as mean ± SEM. Data were analyzed using the appropriate t test, two-way ANOVA, or three-way ANOVA. When appropriate, Tukey post hoc comparisons were used to determine pair-wise differences between groups. P < 0.05 was considered significant for each of these analyses. Data were analyzed using GraphPad (Prism, San Diego, CA) and SigmaStat (Systat Software, Chicago, IL).

Experiment 1: Postprandial GLP-1 in VSG-operated mice.

Fifteen minutes after a mixed-meal gavage, VSG-operated mice exhibited much higher total plasma GLP-1 levels than sham-operated controls (Fig. 1A; t test, P = 0.0002), confirming that mice show a similar GLP-1 response to VSG surgery compared with humans and rats.

Experiment 2: VSG surgery in GLP-1r KO mice.

KO mice weighed significantly less than WT mice at the time of surgery (two-way ANOVA, main effect of genotype, P < 0.0001), which occurred after 5 weeks of exposure to high-fat diet. VSG induced weight loss in both WT and KO mice (Fig. 1B; three-way ANOVA, main effect of genotype), an effect that was sustained for the duration of the experiment. When expressed as a percent change in body weight (Fig. 1C), WT sham and KO sham groups do not significantly differ, nor do WT VSG and KO VSG groups.

Body composition analysis revealed that VSG caused loss of fat mass in both WT and KO animals, with KO mice having less fat mass than the corresponding WT group (Fig. 1D; two-way ANOVA, main effect of genotype, P < 0.001; two-way ANOVA, surgery, P < 0.001). Lean mass was unchanged by the surgery, but lower in KO than in WT mice (Fig. 1E; main effect of genotype, P < 0.001). Percent change of fat mass was similar between WT and KO mice (main effect of surgery, P < 0.001), and percent change of lean mass was similar among all groups (Supplementary Fig. 2).

To verify that the GLP-1r KO mice had functional loss of GLP-1 receptors (in addition to genotyping by PCR), we challenged the mice with an intraperitoneal injection of the GLP-1r agonist exendin-4, which potently decreases food intake by acting on the GLP-1r. WT mice had the predicted hypophagic response, decreasing their 24-h food intake relative to a saline injection, whereas GLP-1r KO mice were unresponsive to the treatment (Fig. 1F; t test, P < 0.0001)

Blood glucose was measured after oral administration of Ensure Plus liquid diet to assess glucose excursions in response to a mixed meal (Fig. 2A). KO sham mice had significantly elevated glucose excursions compared with WT sham (P < 0.001 at 45 min and 60 min), and VSG-operated mice of both genotypes had lower glucose levels than the sham-operated groups and did not differ from each other (WT sham vs. WT VSG P < 0.01 at 30 min; KO sham vs. KO VSG P < 0.05 at 15–120 min). Fasting glucose (baseline for the mixed-meal tolerance test) was significantly lower in VSG-operated mice as compared with sham-operated mice of both genotypes (two-way ANOVA of 0 time point, main effect of surgery, P < 0.0001). Baseline fasting insulin levels revealed an effect of both surgery (P = 0.0068) and genotype (P = 0.0006), with WT and sham animals having higher insulin levels than KO and VSG counterparts (Fig. 2B). At 15 min, WT and KO VSG mice increased insulin levels to a similar extent compared with sham controls (Fig. 2C; main effect of surgery, P = 0.0012).

In the first 3 postoperative days, VSG-operated mice exhibited lower food intake than sham-operated mice of both genotypes (Fig. 2D; two-way ANOVA, main effect of surgery, P < 0.0001) and gradually increased their energy intake through the second postoperative week (Supplementary Fig. 3). Three-day food intake was measured from days 28–31 (Fig. 2D), at which time KO mice ate less than WT mice (Fig. 3D; two-way ANOVA, main effect of genotype, P = 0.008), likely because of the decreased body mass of the KO animals. A macronutrient selection paradigm, in which mice were allowed to self-select their diet from pure macronutrient sources, was used to assess food choice during the second postoperative week (Fig. 2E). VSG altered food choice in WT mice by decreasing fat intake (P < 0.01), increasing carbohydrate intake (P < 0.01), and increasing protein intake (P < 0.01), an effect that we have recently demonstrated in rats (15). VSG had a similar effect in KO mice (fat, P < 0.001; carbohydrate, P < 0.01) but did not alter protein intake (three-way ANOVA surgery × diet, P < 0.001; genotype × diet, P = 0.208).

Experiment 3: VSG surgery in a new model of global GLP-1r deficiency.

GLP-1r flΔCMV mice and CMV-Cre littermate controls were investigated for expression of the loxP-floxed segment of the GLP-1r gene (exons 6 and 7) and normalized to expression of L32. Compared with CMV-Cre controls, GLP-1r flΔCMV mice had negligible GLP-1r expression in pancreas, lung, and hypothalamus (Fig. 3A; t test, P < 0.001 in all cases). A separate cohort of GLP-1r flΔCMV mice and CMV-Cre littermate controls were challenged with an intraperitoneal injection of exendin-4 to determine whether this model of global GLP-1r deficiency was truly insensitive to the hypophagic effect of a potent GLP-1r antagonist. Similar to the results obtained in experiment 2, the control mice significantly decreased their food intake compared with their response to a saline injection, whereas the GLP-1r flΔCMV mice showed no hypophagic response (Fig. 3B; t test, P < 0.0001).

VSG induced weight loss compared with sham-operated mice in both CMV-Cre and GLP-1r flΔCMV mice (Fig. 3C; three-way ANOVA, main effect of genotype, P < 0.001; three-way ANOVA, surgery, P < 0.001), but there was no statistical interaction of genotype and surgery (P = 0.326), indicating that VSG is equally effective in both genotypes.

The results of the mixed-meal tolerance test (Fig. 3D) are similar to the results obtained using the established GLP-1r KO mice (Fig. 2A). VSG-operated mice of both genotypes exhibited a significant improvement in blood glucose excursions, and sham GLP-1r flΔCMV mice tended to be more glucose-intolerant than the sham controls (three-way ANOVA, main effect of surgery, P < 0.001; three ANOVA, genotype, P = 0.015; three-way ANOVA, surgery × genotype interaction, P = 0.679).


Here, we show that mice lacking GLP-1r respond just as well as WT mice after VSG surgery in terms of reduced body weight and body fat improvements in glucose homeostasis and altered food choice. Importantly, VSG overcomes the presurgical glucose intolerance of GLP-1r–deficient mice, decreasing the glucose excursions to WT VSG levels. Given that GLP-1 has been widely hypothesized to be responsible for VSG-induced improvements in glucose tolerance, it is especially surprising that mice that lack GLP-1 action show a paradoxically greater magnitude of improvement than WT animals. Our data demonstrate that large-magnitude improvements in glucose tolerance occur even in the absence of GLP-1r signaling; therefore, GLP-1r activity is not necessary to manifest the beneficial effects of VSG surgery.

We have to admit that these data surprised us. The outcome stands in stark contrast to our original hypothesis and do not directly support the conclusions of several other studies that implicate GLP-1 in the outcomes of RYGB surgery. For example, one 2007 study showed that meal-induced GLP-1 (and peptide YY [PYY]) excursions are higher in RYGB patients with superior weight loss compared with those who did not achieve sufficient weight loss (16). Moreover, the same study showed that somatostatin, which inhibits the release of those hormones from the intestine, increased food intake in RYGB but not in adjustable gastric band patients, in whom GLP-1 and PYY release are not increased. The implication is that more robust GLP-1 and PYY excursions directly reduce food intake and lead to body weight loss.

Three additional reports, including one from our own group, have used the GLP-1r antagonist exendin-9 to demonstrate that surgery-induced improvements in glucose homeostasis are attenuated when GLP-1 action is blocked. Kindel et al. (17) demonstrated that Goto-Kakizaki rats that undergo duodenal-jejunal exclusion exhibit a small improvement in glucose tolerance, but that the effect is abolished after a subcutaneous injection of exendin-9. Similarly, we showed that exendin-9 undermined the improvements in glucose tolerance of RYGB and VSG-operated diet-induced obese rats (10). Finally, a human study of weight-stable RYGB patients demonstrated that meal-stimulated insulin secretion, which is higher in RYGB compared with control subjects, was suppressed to a greater degree by exendin-9 in RYGB patients (18). All of the studies suggest that acute pharmacological manipulation of GLP-1r signaling is sufficient to reduce the benefit of VSG on the response to a glucose load.

Studying a human-specific procedure such as bariatric surgery in an animal model has benefits as well as caveats. In mouse experiments such as these, the inclusion of appropriate control groups, such as sham surgery, as well as the ability to control for many factors (diet, exercise, environment) are clear advantages. However, rodents continue to grow and gain body mass throughout their lifetime. This is different from humans. As such, mice that receive bariatric surgery will likely eventually meet and surpass their presurgical body weight. It is important to note, though, that we and others have found that VSG- or RYGB-operated rodents maintain lower body weight compared with sham-operated controls throughout their lifetime (10,19). Across a wide range of physiological phenomena, effects in rodents closely parallel observations in human bariatric patients, including the dramatic increases in GLP-1 secretion (6,10).

There are a number of advantages to the use of genetic KO models to study the role of GLP-1 in bariatric surgery as compared with these examples of a pharmacological approach. Exogenous administration of the GLP-1r antagonist exendin-9 has several uncertainties, including the degree of GLP-1r blockade, potential nonspecific effects of the antagonist, partial agonist activity, and the temporal period for which the receptor blockade is achieved. The genetic approaches used here provide unequivocal long-term disruption of the GLP-1r in all tissues and consequently provide experimental benefits when trying to examine the effect of a chronic treatment such as a bariatric procedure like VSG. These advantages need to be weighed against the possibility that whole-body genetic KO models of any kind might result in developmental compensation. As such, it is possible that this approach underestimates the roll of GLP-1 to contribute to the effects of VSG. At least two cases of compensation in GLP-1r KO mice have been reported, indicating enhanced action of GLP-2 (20) and glucose-dependent insulinotropic peptide (21) compared with WT controls. Thus, one hypothesis is that the potential increases in gastric inhibitory polypeptide or GLP-2 could compensate for the lack of GLP-1r signaling. However, GIP has been shown to promote fat accumulation (22), which does not fit with the phenotype of the GLP-1r KO mice before or after VSG surgery. Furthermore, even if this were true, it is difficult to reconcile why the GLP-1r KO mice do not have normal glucose tolerance until after VSG. Regarding the role of GLP-2, although it may decrease food intake, it has no known effects on glucose tolerance (22). Thus, although developmental compensation is a potential explanation for results such as these, there is not a straightforward hypothesis about the nature of developmental compensation that would account for the present data.

Here, the GLP-1r KO mice from experiment 2 had lower body weight and fat mass than the WT controls both before and after surgery. Although we can offer no explanation why lack of GLP-1r signaling would cause this phenotype, our data fit with previous reports (12,23) that showed that GLP-1r KO mice maintained on chow diet had similar body weight compared with weight-type controls, but gained less weight than WT mice when maintained on a high-fat diet. Our mice were maintained on high-fat diet from the time of weaning to induce the diet-induced obese phenotype. Thus, our results fit with previous reports of reduced weight gain after high-fat feeding of GLP-1r KO mice. Despite this difference in presurgical body weight, the response to surgery is clearly parallel between the two genotypes.

In conclusion, the studies described here, like all lack-of-function experiments, test whether a factor (in this case, the GLP-1r) is necessary for the effect of interest. They do not address whether that same factor is sufficient for the effect or whether it may play some other kind of role. As such, we cannot rule out that GLP-1 may contribute to the effects of VSG, including weight loss, glucose tolerance, and altered food choice. However, we can say with certainty that it is not strictly necessary. Thus, because the GLP-1r is not required to manifest the dramatic effects of VSG, other factors or systems must contribute to the beneficial effects of VSG.

Using two independent models of genetic disruption of the GLP-1r, our data clearly demonstrate that GLP-1r activity is not necessary for VSG to exert its potent effects on a range of metabolic and behavioral end points. Given the similarity of the enhanced postprandial GLP-1 responses in both VSG and RYGB (4,6,10), as well as their similar effects on insulin secretion, hepatic glucose production, and food choice (4,10,15), the primacy of GLP-1 as the primary mediator of the pleiotropic metabolic benefits of bariatric surgery requires reconsideration.

Supplementary Material Supplementary Data


fn1This article contains Supplementary Data online at


This work was supported by National Institutes of Health grants DK54890 and DK82480 and Ethicon Endo-Surgery. H.E.W.-P. is supported by National Institutes of Health training grant T32 HD07463 and by a grant from the Ryan Foundation.

D.J.D. is supported by the Canada Research Chairs program and by the BBDC Novo Nordisk Chair in incretin biology. D.A.S. and D.P.-T. receive research support from Ethicon Endo-Surgery. D.J.D. is a consultant to Arisaph, GSK, Lilly, Merck, Novo Nordisk, and Sanofi, and receives research support from GSK, Merck, and Novo Nordisk. R.J.S. receives research support from Ethicon Endo-Surgery, serves on a Scientific Advisory Board, and has been a paid speaker for Ethicon Endo-Surgery. No other potential conflicts of interest relevant to this article were reported.

H.E.W.-P. led the project in study concept/design, data acquisition, analysis, and manuscript writing. A.P.C. and K.K.R. assisted with data acquisition and interpretation. B.L. generated, validated, and phenotyped mouse models. D.A.S. assisted with interpretation of data and critical manuscript revision. D.S. generated, validated, and phenotyped mouse models. D.J.D. and D.P.-T. contributed material support and critically revised the manuscript. R.J.S. obtained funding and provided study supervision. R.J.S. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank Jose Berger, Alfor Lewis, Ken Parks, and Mouhamadoul Toure (University of Cincinnati) for expert technical assistance with the mouse surgical procedures.

1. Drucker DJ,Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. LancetYear: 2006;368:1696–170517098089
2. Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol MetabYear: 2008;93(Suppl. 1):S89–S9618987275
3. Abbatini F,Rizzello M,Casella G,et al. Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg EndoscYear: 2010;24:1005–101019866235
4. Karamanakos SN,Vagenas K,Kalfarentzos F,Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann SurgYear: 2008;247:401–40718376181
5. Pereferrer FS,Gonzàlez MH,Rovira AF,Blasco SB,Rivas AM,del Castillo Déjardin D. Influence of sleeve gastrectomy on several experimental models of obesity: metabolic and hormonal implications. Obes SurgYear: 2008;18:97–10818066699
6. Peterli R,Wölnerhanssen B,Peters T,et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann SurgYear: 2009;250:234–24119638921
7. Stefater MA, Perez-Tilve D, Chambers AP, et al. Sleeve gastrectomy induces loss of weight and fat mass in obese rats, but does not affect leptin sensitivity. Gastroenterology 2010;138:2426–2436, e2421–e2423
8. Stefater MA, Sandoval DA, Chambers AP, et al. Sleeve gastrectomy in rats improves postprandial lipid clearance by reducing intestinal triglyceride secretion. Gastroenterology 2011;141:939–949, e931–e934
9. Schauer PR,Kashyap SR,Wolski K,et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J MedYear: 2012;366:1567–157622449319
10. Chambers AP,Jessen L,Ryan KK,et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. GastroenterologyYear: 2011;141:950–95821699789
11. Cummings DE,Overduin J,Shannon MH,Foster-Schubert KE,2004 ABS Consensus ConferenceHormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Surg Obes Relat DisYear: 2005;1:358–36816925248
12. Ayala JE,Bracy DP,James FD,Burmeister MA,Wasserman DH,Drucker DJ. Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. EndocrinologyYear: 2010;151:4678–468720685876
13. Scrocchi LA,Brown TJ,MaClusky N,et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat MedYear: 1996;2:1254–12588898756
14. Schwenk F,Baron U,Rajewsky K. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids ResYear: 1995;23:5080–50818559668
15. Wilson-Perez HE,Chambers AP,Sandoval DA,et al. The effect of vertical sleeve gastrectomy on food choice in rats. Int J Obes (Lond)Year: 2013;37:288–295
16. le Roux CW,Welbourn R,Werling M,et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann SurgYear: 2007;246:780–78517968169
17. Kindel TL,Yoder SM,Seeley RJ,D’Alessio DA,Tso P. Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. J Gastrointest SurgYear: 2009;13:1762–177219488823
18. Salehi M,Prigeon RL,D’Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. DiabetesYear: 2011;60:2308–231421868791
19. Stylopoulos N,Hoppin AG,Kaplan LM. Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. Obesity (Silver Spring)Year: 2009;17:1839–184719556976
20. Lovshin J,Estall J,Yusta B,Brown TJ,Drucker DJ. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol ChemYear: 2001;276:21489–2149911262390
21. Pederson RA,Satkunarajah M,McIntosh CH,et al. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. DiabetesYear: 1998;47:1046–10529648827
22. Meier JJ,Nauck MA. GIP as a potential therapeutic agent?Horm Metab ResYear: 2004;36:859–86615655720
23. Hansotia T,Maida A,Flock G,et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin InvestYear: 2007;117:143–15217187081


[Figure ID: F1]
FIG. 1. 

The effect of VSG on body weight and body fat in GLP-1r KO mice. VSG-operated mice (n = 5 VSG; n = 7 sham) show significantly elevated plasma GLP-1 15 min after gavage of a mixed meal (A). After 5 weeks of high-fat feeding, GLP-1r WT and KO mice underwent VSG or sham surgery (n = 8 WT sham; n = 11 WT VSG; n = 12 KO sham; and n = 16 KO VSG). Body weight (B) and weight change from the time of surgery (C) were monitored, and body composition (D and E) was assessed on postoperative day 21. The food intake response to the GLP-1r agonist exendin-4 (F) is shown as the difference between 24-h food intake after exendin-4 and saline treatment. Data are represented as mean ± SEM. *P < 0.05; ***P < 0.001.

[Figure ID: F2]
FIG. 2. 

Metabolic effects of VSG in GLP-1r KO mice. GLP-1r WT and KO mice that received VSG or sham surgery underwent a mixed-meal tolerance test on postoperative day 18 (n = 8 WT sham; n = 11 WT VSG; n = 12 KO sham; and n = 16 KO VSG). Blood glucose (A) was measured after gavage of a standard liquid diet, and plasma insulin was determined at baseline (B) and 15 min (C). Food intake (D) was significantly lower in VSG-operated mice of both genotypes from days 0–3, but by days 28–31 there was no effect of surgery and KO mice consumed less than WT controls. Food choice was assessed by macronutrient selection (n = 6 WT sham; n = 7 WT VSG; n = 9 KO sham; and n = 12 KO VSG), showing that VSG mice of both genotypes decrease fat intake and increase carbohydrate intake (E). Data are represented as mean ± SEM. **P < 0.01; ***P < 0.001.

[Figure ID: F3]
FIG. 3. 

VSG in a new model of GLP-1r deficiency. Expressions of GLP-1r exons 6 and 7 were analyzed in pancreas, lung, and hypothalamus of CMV-Cre (control n = 6) and GLP-1r flΔCMV (KO n = 9) mice (A). Mice were tested for their food intake response to the GLP-1r agonist exendin-4 (B). Data are shown as the difference between 24-h food intake after exendin-4 and saline treatment. Body weight change (C) was monitored after VSG or sham surgery (control sham n = 7; control VSG n = 7; KO sham n = 11; KO VSG n = 17), and a mixed-meal tolerance test (D) was conducted 5 weeks postoperatively. Data are represented as mean ± SEM. ***P < 0.001.

Article Categories:
  • Original Research
    • Obesity Studies

Previous Document:  Systemic free fatty acid disposal into very low-density lipoprotein triglycerides.
Next Document:  Combined cholecystectomy in gastric cancer surgery.